- Home
- SRG vs ZNTL Comparison
SRG vs ZNTL Comparison
Compare SRG & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRG
- ZNTL
- Stock Information
- Founded
- SRG 2014
- ZNTL 2014
- Country
- SRG United States
- ZNTL United States
- Employees
- SRG N/A
- ZNTL N/A
- Industry
- SRG Real Estate Investment Trusts
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- SRG Real Estate
- ZNTL Health Care
- Exchange
- SRG Nasdaq
- ZNTL Nasdaq
- Market Cap
- SRG 238.6M
- ZNTL 227.0M
- IPO Year
- SRG 2015
- ZNTL 2020
- Fundamental
- Price
- SRG $4.13
- ZNTL $2.94
- Analyst Decision
- SRG
- ZNTL Buy
- Analyst Count
- SRG 0
- ZNTL 8
- Target Price
- SRG N/A
- ZNTL $10.50
- AVG Volume (30 Days)
- SRG 273.7K
- ZNTL 1.0M
- Earning Date
- SRG 11-12-2024
- ZNTL 02-25-2025
- Dividend Yield
- SRG N/A
- ZNTL N/A
- EPS Growth
- SRG N/A
- ZNTL N/A
- EPS
- SRG N/A
- ZNTL N/A
- Revenue
- SRG $56,359,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- SRG N/A
- ZNTL N/A
- Revenue Next Year
- SRG N/A
- ZNTL N/A
- P/E Ratio
- SRG N/A
- ZNTL N/A
- Revenue Growth
- SRG N/A
- ZNTL N/A
- 52 Week Low
- SRG $3.63
- ZNTL $2.66
- 52 Week High
- SRG $9.87
- ZNTL $18.07
- Technical
- Relative Strength Index (RSI)
- SRG 44.52
- ZNTL 41.88
- Support Level
- SRG $3.98
- ZNTL $2.80
- Resistance Level
- SRG $4.25
- ZNTL $3.32
- Average True Range (ATR)
- SRG 0.15
- ZNTL 0.24
- MACD
- SRG -0.01
- ZNTL -0.02
- Stochastic Oscillator
- SRG 28.45
- ZNTL 16.52
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.